Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors

IVERIC bio, Inc. (Nasdaq: ISEE) announced today the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to shape the Company’s business strategy and in overseeing the development and regulatory submission process for avacincaptad pegol (ACP, also known as Zimura) since he joined Iveric Bio in 2020.

“On behalf of the entire Board of Directors, we are excited to have Pravin join our board during this pivotal time as the Company prepares for a potential approval and commercial launch of ACP in geographic atrophy,” stated Adrienne L. Graves, PhD, Chairman of the Board of Iveric Bio.

“Pravin is an exceptional leader whose skills as an executive and extensive knowledge as a retinal specialist provide a valued perspective that will enhance the collective experience of our Board,” stated Glenn P. Sblendorio, Chief Executive Officer of Iveric Bio. “I enjoy working closely with Pravin and now look forward to working with him in his added role as a board member. We are committed to executing our plan to deliver value to our shareholders.”

“I look forward to adding to my responsibilities by serving as a board member of the Company and I am particularly honored to be among this group of talented and diverse board members,” stated Pravin U. Dugel, MD, President of Iveric Bio. “Following the successful results from our Phase 3 ACP clinical trials, I believe we have the potential to transform the AMD treatment landscape by bringing a breakthrough therapy to patients impacted by geographic atrophy.”

Pravin U. Dugel, MD
Dr. Dugel is currently the President of Iveric Bio. He joined as Executive Vice President in April 2020 and was promoted to President of the Company in May 2021. Dr. Dugel has over 26 years of experience as a retina specialist. Dr. Dugel was previously Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; and Founding Member, Spectra Eye Institute in Sun City, Arizona. Dr. Dugel has authored more than 200 papers, 35 book chapters and has been invited to lecture at several marquis medical meetings and to serve as a visiting professor at universities worldwide, including in Japan, India, China, Malaysia, Egypt, the United Kingdom, France, Germany, Austria, Italy, Poland, Denmark, Norway, Czechoslovakia, Canada and Australia. Dr. Dugel is internationally recognized as a major clinical researcher and has been a principal investigator in over 100 multicenter clinical trials. His research and educational contributions earned him the prestigious Senior Honor Award from the American Academy of Ophthalmology (AAO). He has been elected and previously served as the Retina Subspecialty Day Board Chairman for the American Academy of Ophthalmology Annual Meeting, as a member of the Board of Directors of the largest retina society in the United States, the American Society of Retina Specialists (ASRS), and the largest retina society in Europe, EURETINA.